The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study

Creative Commons License

GÜVEN D. C., YILDIRIM H. Ç., ERUL E., ŞAHİN T. K., ÇAKIR İ. Y., AKTEPE O. H., ...More

TURKISH JOURNAL OF MEDICAL SCIENCES, vol.52, no.5, pp.1551-1558, 2022 (SCI-Expanded) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 52 Issue: 5
  • Publication Date: 2022
  • Doi Number: 10.55730/1300-0144.5495
  • Journal Name: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.1551-1558
  • Keywords: Fulvestrant, hormone-positive, breast cancer, real-life, FALCON study, 500 MG, POSTMENOPAUSAL WOMEN, METAANALYSIS, TRASTUZUMAB, LETROZOLE, THERAPY
  • Hacettepe University Affiliated: Yes

Abstract

Background/aim: We aimed to evaluate the efficacy of fulvestrant and its affecting clinical factors, including the optimal sequencing of fulvestrant and chemotherapy in a real-life cohort.